TW202200119A - 利用粉狀鼻內腎上腺素的治療物及方法 - Google Patents

利用粉狀鼻內腎上腺素的治療物及方法 Download PDF

Info

Publication number
TW202200119A
TW202200119A TW110109439A TW110109439A TW202200119A TW 202200119 A TW202200119 A TW 202200119A TW 110109439 A TW110109439 A TW 110109439A TW 110109439 A TW110109439 A TW 110109439A TW 202200119 A TW202200119 A TW 202200119A
Authority
TW
Taiwan
Prior art keywords
epinephrine
pharmaceutical composition
solid particles
type
particle size
Prior art date
Application number
TW110109439A
Other languages
English (en)
Chinese (zh)
Inventor
克雷茲 加利亞 鐵姆辛
帕維爾 卡茲丹
Original Assignee
以色列商納蘇斯製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 以色列商納蘇斯製藥有限公司 filed Critical 以色列商納蘇斯製藥有限公司
Publication of TW202200119A publication Critical patent/TW202200119A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110109439A 2020-03-16 2021-03-16 利用粉狀鼻內腎上腺素的治療物及方法 TW202200119A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US62/989,913 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
US17/135,528 2020-12-28

Publications (1)

Publication Number Publication Date
TW202200119A true TW202200119A (zh) 2022-01-01

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110109439A TW202200119A (zh) 2020-03-16 2021-03-16 利用粉狀鼻內腎上腺素的治療物及方法

Country Status (13)

Country Link
US (2) US11400045B2 (https=)
EP (1) EP4121005A1 (https=)
JP (1) JP2023517532A (https=)
KR (1) KR20220154709A (https=)
CN (1) CN115279340A (https=)
AR (1) AR121593A1 (https=)
AU (1) AU2021239084A1 (https=)
BR (1) BR112022018440A2 (https=)
CA (1) CA3175130A1 (https=)
IL (1) IL296268A (https=)
MX (1) MX2022011464A (https=)
TW (1) TW202200119A (https=)
WO (1) WO2021186437A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20250048076A (ko) * 2022-08-11 2025-04-07 드 모투 코르디스 피티와이 엘티디 흡입형 에피네프린 제형
TW202502309A (zh) * 2023-05-31 2025-01-16 瑞典商奥瑞克索股份公司 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
MX2016002705A (es) 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
EP3668490A4 (en) * 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
GB2600026B (en) * 2018-02-06 2022-10-12 Aegis Therapeutics Llc Intranasal epinephrine formulations and methods for the treatment of disease
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Also Published As

Publication number Publication date
CA3175130A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
WO2021186437A1 (en) 2021-09-23
KR20220154709A (ko) 2022-11-22
BR112022018440A2 (pt) 2022-11-01
MX2022011464A (es) 2022-11-14
US20210283050A1 (en) 2021-09-16
US11400045B2 (en) 2022-08-02
IL296268A (en) 2022-11-01
US20230105615A1 (en) 2023-04-06
AR121593A1 (es) 2022-06-22
CN115279340A (zh) 2022-11-01
JP2023517532A (ja) 2023-04-26
AU2021239084A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
TW202200119A (zh) 利用粉狀鼻內腎上腺素的治療物及方法
JP7071949B2 (ja) 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
EP2943181B1 (en) Pharmaceutical compositions
KR101763195B1 (ko) 건조 분말 반코마이신 조성물 및 관련 방법
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
MX2007012084A (es) Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
CN102724974A (zh) 毒蕈碱受体拮抗剂和β-2肾上腺素受体激动剂的组合
US20230355552A1 (en) Pharmaceutical composition comprising adrenaline
US12303472B2 (en) Pharmaceutical device for use in intranasal administration
WO2013104892A1 (en) Application of high dose compounds via inhalation
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
JP2024502236A (ja) 心房性不整脈を有する対象におけるカルディオバージョンの誘導のためのキットおよび方法
MXPA05001901A (es) Composiciones para inhalacion con altas proporciones de medicamento.
US20140377365A1 (en) Sustained-release formulation of rotigotine
KR19990021931A (ko) 미세구형 전분의 항편두통 조성물
Hickey Introduction: A Guide to Treatment and Prevention of Tuberculosis Based on Principles of Dosage Form Design and Delivery